2 résultats
Sites of relapse and subsequent therapy in the BR.31 phase 3 study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
Auteurs / Authors
V. Westeel
, G. Goss
, G. Darling
, K. Nakagawa
, B. Massuti Sureda
,
F. Perrone
, S-A. McLachlan
, J.H. Kang
, Y-L. Wu
,A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier,
C. Audigier-Valette, F. Morin, S. Sugawara, E. Nadal,
M.R. Stockler, K. Ding, C. O’Callaghan
Journal / Conference
ELCC
Année / Year
2025
PMID / session
Etude IFCT
CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Auteurs / Authors
G. Goss, G.E. Darling, V. Westeel, K. Nakagawa, B. Massuti Sureda, F. Perrone, S-A. McLachlan, J.H. Kang, Y-L. Wu, A-M.C. Dingemans, R. Dziadziuszko, M. Okada, L. Greillier, C. Audigier-Valette, S. Sugawara, E. Nadal, A. Catino, M.R. Stockler, K. Ding, C. O’Callaghan
Journal / Conference
ESMO
Année / Year
2024
PMID / session
Etude IFCT